# EDGAR Filing Document

**Accession Number:** 0001723464
**File Stem:** 0001139020-25-000315
**Filing Date:** 2025-9
**Character Count:** 9148
**Document Hash:** 1cf917d3d52a2f20f676d2a12f510604
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001139020-25-000315.hdr.sgml**: 20250910

**ACCESSION NUMBER**: 0001139020-25-000315

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250910

**FILED AS OF DATE**: 20250910

**DATE AS OF CHANGE**: 20250910

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOHARVEST SCIENCES INC.
- **CENTRAL INDEX KEY:** 0001723464
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42389
- **FILM NUMBER:** 251306144

**BUSINESS ADDRESS:**
- **STREET 1:** 1140 - 625 HOWE STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 2T6
- **BUSINESS PHONE:** 6046221186

**MAIL ADDRESS:**
- **STREET 1:** 1140 - 625 HOWE STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 2T6

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CANNA-V-CELL SCIENCES INC.
- **DATE OF NAME CHANGE:** 20191008

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Midnight Star Ventures Corp.
- **DATE OF NAME CHANGE:** 20171121

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **September 2025**

Commission file number: **001-42389**

**BIOHARVEST SCIENCES INC.**

(Exact name of Registrant as specified in its charter)

**Not applicable**

(Translation of Registrant's name into English)

**1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☐ Form 20-F ☒ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

**SUBMITTED HEREWITH**

**Exhibits:**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Exhibit** | &nbsp;&nbsp;**Description** |
| &nbsp;&nbsp;[99.1](bhsc_ex991.htm) | &nbsp;&nbsp;News Release dated September 10, 2025 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;**BIOHARVEST SCIENCES INC.** |
|  | &nbsp;&nbsp;(Registrant) |
| &nbsp;&nbsp;Date: September 10, 2025 | &nbsp;&nbsp;*/s/ David Ryan* |
|  | &nbsp;&nbsp;Name: David Ryan |
|  | &nbsp;&nbsp;Title: Vice-President, Investor Relations & Secretary |

---

## Exhibit 99.1

**BioHarvest Sciences Announces Breakthrough in Botanical Synthesis Capabilities with Plant-Based Exosome Production at Scale** 

*Exosomes Produced in the Liquid Media of the BioHarvest Unique Large-Scale Bioreactors Add Potential New Revenue Stream from Products and CDMO Opportunities*

**Rehovot, Israel – September 10, 2025 –** BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that is has successfully produced, at scale, plant-based exosomes in its bioreactor media, marking a significant advancement in the Company's proprietary Botanical Synthesis platform and its ability to generate new revenue streams.

Exosomes are nano-sized extracellular vesicles naturally secreted by plant cells, with bioactive properties with enhanced absorption and bioavailability levels versus regular plant compounds. They are becoming highly sought after in a wide range of therapeutic and cosmetic applications, including targeted drug delivery, tissue regeneration, anti-inflammatory treatments, and advanced skincare formulations.

BioHarvest's bioreactors are designed to do more than grow plant cells—they create the ideal environment for high-yield, high-value exosomes. By combining optimized growth media with light-permeable bioreactors, the BioHarvest system naturally drives cells to release exosomes that are enriched with important metabolites. This unique combination delivers superior yields and superior cargo quality, setting BioHarvest apart from conventional plant or animal-derived systems. The result is a scalable, cost-efficient, and defensible advantage that opens powerful new revenue streams for CDMO customers in cosmetics, health, and pharma.

BioHarvest's exosomes are produced in its large scale VINIA® bioreactors, and contain viniferin, a polyphenol prized for anti-aging, firming, brightening, and antioxidant benefits in skincare applications. Unlike conventional viniferin formulations used by international cosmetic companies, BioHarvest's plant-derived exosomes provide a novel and more efficacious delivery vehicle for viniferin, as their nano-sized structure enhances absorption and bioavailability in the skin compared to conventional formulations.

Ilan Sobel, CEO of BioHarvest Sciences, commented:

"We are always pushing the boundaries of our Botanical Synthesis technology and the capabilities of our bioreactors, and we have now proven that our bioreactors can efficiently produce plant-based exosomes, a high-value class of biomolecules with significant potential in health and cosmetic industries. We expect that within 18 to 24 months, we will be in a position to bring a new, highly differentiated skin care application to the market, using exosomes to carry viniferin in a more efficacious way.

With growing scientific validation and global exosome market demand expected to grow from $0.7B in 2025 to $2.2B by 2030\*, plant-based exosomes are emerging as a safer, non-animal-derived alternative to synthetic or mammalian counterparts. This development represents a significant new bonus layer of value from our core technology and could serve as an exciting new monetization path."

------

**BioHarvest Investor Webinar - Today, September 10, 2025, at 1 pm ET**

CEO Ilan Sobel will host an online investor webinar to provide a corporate update on new capability-building initiatives, the Company's 'Big Bets' for 2H 2025, and will conclude with a question-and-answer session from dial-in participants. To attend, please reference the access information below:

Date: Wednesday, September 10, 2025

Time: 1:00 p.m. Eastern time

Webcast link: BHST Virtual Investor Webinar

**About BioHarvest Sciences Inc.**

BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

**Forward-Looking Statements**

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts. Readers are cautioned that future contracts or increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that the global exosome market demand will grow, or that a future exosome product will be launched within the next 18-14 months, as launching new products is subject to risks and uncertainties including the risk that the market will not accept the product or that government approvals required for sale or import of the products will not be obtained. All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

\*Global Exosomes Market Research Report on Size, Share& Growth Analysis – Mordor Intelligence

(https://www.mordorintelligence.com/industry-reports/exosomes-market)

**BioHarvest Corporate Contact:**<br>Dave Ryan, VP Investor Relations <br>(604) 622-1186<br>info@bioharvest.com

**Investor Relations Contact:**<br>Lucas A. Zimmerman<br>Managing Director<br>MZ Group - MZ North America<br>(949) 259-4987<br>BHST@mzgroup.us